Yibo Fan1,2, Yunpeng Liu3,4, Xiujuan Qu1. 1. Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. 2. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China. 3. Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. cmuliuyunpeng@hotmail.com. 4. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China. cmuliuyunpeng@hotmail.com.
Authors: Hao Wu; Mengdi Fu; Jin Liu; Wei Chong; Zhen Fang; Fengying Du; Yang Liu; Liang Shang; Leping Li Journal: Mol Cancer Date: 2021-04-29 Impact factor: 27.401